Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lung Diseases × zimberelimab × Thoracic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 9 Lung Neoplasms 3 Uterine Cervical Neoplasms 2 Stomach Neoplasms 2 Esophageal Neoplasms 2 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Thymoma 1 Squamous Cell Carcinoma of Head and Neck 1 Ovarian Neoplasms 1 Multiple Myeloma 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Large B-Cell, Diffuse 1 Lung Diseases 1 Gestational Trophoblastic Disease 1 Gastro-enteropancreatic neuroendocrine tumor 1 Carcinoma, Renal Cell 1 Carcinoid Tumor 1 Advanced Non-Small Cell Lung Cancer 1

Interventions

Carboplatin 15 Pemetrexed 8 pembrolizumab 5 Paclitaxel 5 Cisplatin 5 Nivolumab 4 osimertinib 3 entinostat 3 atezolizumab 3 Erlotinib Hydrochloride 3 selpercatinib 2 pralsetinib 2 durvalumab 2 camrelizumab 2 apatinib 2 One-Lung Ventilation 2 Ipilimumab 2 Bevacizumab 2 130-nm albumin-bound paclitaxel 2 zipalertinib 1 zimberelimab 1 toripalimab 1 taletrectinib 1 spartalizumab 1 sotorasib 1 sitravatinib 1 sintilimab 1 sacituzumab govitecan 1 repotrectinib 1 patritumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06431633 2025-04-10

ARIAN

Fundación GECP

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡